Abiopharma

🔍 Bryson Anna (Executive)

Company: Doximity, Inc. (DOCS)

Report Date: 2025-08-26

Detailed Transactions and Holdings:

• Acquired 40,000 shares of Class A Common Stock (Direct)
  Date: 2025-08-26 | Code: C | equity_swap_involved: 0 | shares_owned_after: 386,925.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 40,000 shares of Class A Common Stock at $66.7561 per share (Direct)
  Date: 2025-08-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 346,925.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 40,000 shares of Stock Option (Right to Buy) at $8.26 per share (Derivative)
  Date: 2025-08-26 | Code: M | Expires: 2031-02-04 | equity_swap_involved: 0 | shares_owned_after: 247,268.00 | transaction_form_type: 4 | Footnotes: F4, F5
• Acquired 40,000 shares of Class B Common Stock (Derivative)
  Date: 2025-08-26 | Code: M | equity_swap_involved: 0 | shares_owned_after: 40,000.00 | transaction_form_type: 4 | Footnotes: F5, F5, F5
• Sold 40,000 shares of Class B Common Stock (Derivative)
  Date: 2025-08-26 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5, F1, F5, F5

Footnotes:

• F1: Each share of Class B Common Stock, par value $0.001 per share (the "Class B Common Stock"), converted into one share of Class A Common Stock, par value $0.001 per share (the "Class A Common Stock"), at the option of the holder.
• F2: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 27, 2025.
• F3: The price represents the weighted-average price of the shares sold in multiple transactions ranging from $66.2250 to $67.2200 per share, inclusive. The Reporting Person undertakes to provide the Issuer, a security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The stock option vests in 60 equal monthly installments after February 1, 2021, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The stock option was granted on February 5, 2021.
• F5: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at any time at the option of the holder. Each share of Class B Common Stock held by the Reporting Person will automatically convert into one share of Class A Common Stock, upon the following: (1) the sale or transfer of such share of Class B Common Stock, except for certain permitted transfers described in the Issuer's amended and restated certificate of incorporation; (2) the death or incapacity of the Reporting Person; and (3) on the final conversion date, defined as the earlier of (a) the tenth anniversary of the effectiveness of the registration statement in connection with the Issuer's initial public offering; or (b) the date specified by a vote of the holders of at least 66 2/3% of the outstanding shares of Class B Common Stock, voting as a single class.